MERCK & COMPANY INC (NYSE: MRK)

MERCK & COMPANY INC

NYSE: MRK (Merck & Company, Inc.)

最近更新时间: 4天之前, 2:37PM

75.88

-0.94 (-1.23%)

加入群组

前收盘价格	76.82
收盘价格	77.02
成交量	7,983,851
平均成交量 (3个月)	16,543,009
市值	190,524,407,808

市盈率 (P/E TTM)	11.03
预期市盈率 (P/E Forward)	9.29
价格/销量 (P/S)	3.30
股市价格/股市净资产 (P/B)	4.52

52周波幅	73.31 (-3%) — 134.63 (77%)
利润日期	29 Jul 2025
股息率 (DY TTM)	4.17%

市场趋势

		短期	中期
行业	Drug Manufacturers - General (US)	看跌	混合的
	Drug Manufacturers - General (全球的)	看跌	混合的
股票	Merck & Company, Inc.	看跌	看跌

AIStockmoo 评分

1.1

分析师共识	1.0
内部交易活动	NA
价格波动	1.5
技术平均移动指标	2.5
技术振荡指标	-0.5
平均	1.13

相关股票

股票	市值	DY	P/E（TTM）	P/B
MRK	191 B	4.17%	11.03	4.52
NVS	227 B	3.52%	18.01	5.80
LLY	662 B	0.56%	59.88	45.23
NVO	328 B	2.21%	20.45	13.27
JNJ	372 B	2.40%	17.22	4.73
ABBV	321 B	3.51%	77.36	229.94

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
部门	Healthcare
行业	Drug Manufacturers - General
投资方式	Large Core
内部持股比例	0.08%
机构持股比例	80.43%

52周波幅	73.31 (-3%) — 134.63 (77%)
目标价格波幅	84.00 (10%) — 115.00 (51%)
高	115.00 (Guggenheim, 51.57%)	购买
中	85.00 (12.03%)
低	84.00 (Citigroup, 10.71%)	保留
平均值	94.67 (24.77%)
总计	1 购买, 2 保留
平均价格@调整类型	76.81

公司	日期	目标价格	调整类型	价格@调整类型
Citigroup	14 May 2025	84.00 (10.71%)	保留	73.47
Cantor Fitzgerald	22 Apr 2025	85.00 (12.03%)	保留	78.97
Guggenheim	17 Apr 2025	115.00 (51.57%)	购买	78.00

该时间范围内无数据。

日期	类型	细节
04 Jun 2025	公告	Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
31 May 2025	公告	KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)
30 May 2025	公告	Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations
30 May 2025	公告	Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial
29 May 2025	公告	Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn
27 May 2025	公告	Merck Announces Third-Quarter 2025 Dividend
22 May 2025	公告	Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference
19 May 2025	公告	IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
16 May 2025	公告	Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension
15 May 2025	公告	Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers
14 May 2025	公告	FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)
13 May 2025	公告	Research on Novel Treatment Approaches and Scientific Advances From Merck’s Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025
12 May 2025	CNBC	Trump signs order aiming to cut some U.S. drug prices to match lower ones abroad
12 May 2025	CNBC	Trump's plan to slash drug prices may struggle to get off the ground – here's what to know
08 May 2025	公告	Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto
07 May 2025	公告	Merck to Participate in the Bank of America 2025 Global Healthcare Conference
29 Apr 2025	公告	Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware
27 Apr 2025	公告	KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
24 Apr 2025	公告	Merck Announces First-Quarter 2025 Financial Results
24 Apr 2025	CNBC	Corporate America shelled out millions for Trump's inauguration. Now he's upending many of their businesses
24 Apr 2025	CNBC	Merck lowers profit outlook, partly due to $200 million expected tariff hit
09 Apr 2025	CNBC	Pharmaceutical stocks rise as Trump pauses tariffs but not for China
01 Apr 2025	公告	Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24
31 Mar 2025	公告	WINREVAIR™ (sotatercept-csrk) Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76% Compared to Placebo in the Phase 3 ZENITH Trial
27 Mar 2025	公告	Merck’s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA® (pembrolizumab) in Pivotal 3475A-D77 Trial
26 Mar 2025	公告	European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
25 Mar 2025	公告	Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
19 Mar 2025	公告	Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease
12 Mar 2025	公告	Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48
11 Mar 2025	公告	Merck Unveils New Facility to Increase Vaccine Production Capacity
显示更多

股息率 (DY TTM)	4.17%
5年平均股息收益率	2.96%
股息支付比率	45.93%
预计下次股息支付	Jul 2025

除息日	公告日期	支付日期	详情
17 Mar 2025	28 Jan 2025	07 Apr 2025	0.81 现金
16 Dec 2024	19 Nov 2024	08 Jan 2025	0.81 现金
16 Sep 2024	23 Jul 2024	07 Oct 2024	0.77 现金
17 Jun 2024	28 May 2024	08 Jul 2024	0.77 现金
14 Mar 2024	23 Jan 2024	05 Apr 2024	0.77 现金
14 Dec 2023	28 Nov 2023	08 Jan 2024	0.77 现金
14 Sep 2023	25 Jul 2023	06 Oct 2023	0.73 现金
14 Jun 2023	23 May 2023	10 Jul 2023	0.73 现金
14 Mar 2023	24 Jan 2023	10 Apr 2023	0.73 现金
14 Dec 2022	29 Nov 2022	09 Jan 2023	0.73 现金
14 Sep 2022	26 Jul 2022	07 Oct 2022	0.69 现金
14 Jun 2022	24 May 2022	08 Jul 2022	0.69 现金
14 Mar 2022	25 Jan 2022	07 Apr 2022	0.69 现金
14 Dec 2021	30 Nov 2021	07 Jan 2022	0.69 现金
14 Sep 2021	27 Jul 2021	07 Oct 2021	0.65 现金
14 Jun 2021	25 May 2021	07 Jul 2021	0.65 现金
12 Mar 2021	26 Jan 2021	07 Apr 2021	0.65 现金
14 Dec 2020	17 Nov 2020	08 Jan 2021	0.65 现金
14 Sep 2020	28 Jul 2020	07 Oct 2020	0.61 现金
12 Jun 2020	26 May 2020	07 Jul 2020	0.61 现金
13 Mar 2020	28 Jan 2020	07 Apr 2020	0.61 现金
13 Dec 2019	20 Nov 2019	08 Jan 2020	0.61 现金
13 Sep 2019	24 Jul 2019	07 Oct 2019	0.55 现金
14 Jun 2019	29 May 2019	08 Jul 2019	0.55 现金
14 Mar 2019	30 Jan 2019	05 Apr 2019	0.55 现金
14 Dec 2018	26 Oct 2018	08 Jan 2019	0.55 现金
14 Sep 2018	25 Jul 2018	05 Oct 2018	0.48 现金
14 Jun 2018	23 May 2018	09 Jul 2018	0.48 现金
14 Mar 2018	24 Jan 2018	06 Apr 2018	0.48 现金
14 Dec 2017	29 Nov 2017	08 Jan 2018	0.48 现金
14 Sep 2017	26 Jul 2017	06 Oct 2017	0.47 现金
13 Jun 2017	24 May 2017	10 Jul 2017	0.47 现金
13 Mar 2017	28 Feb 2017	07 Apr 2017	0.47 现金
13 Dec 2016	22 Nov 2016	09 Jan 2017	0.47 现金
13 Sep 2016	26 Jul 2016	07 Oct 2016	0.46 现金
13 Jun 2016	25 May 2016	08 Jul 2016	0.46 现金
11 Mar 2016	24 Feb 2016	07 Apr 2016	0.46 现金
11 Dec 2015	24 Nov 2015	08 Jan 2016	0.46 现金
11 Sep 2015	22 Jul 2015	07 Oct 2015	0.45 现金
11 Jun 2015	26 May 2015	08 Jul 2015	0.45 现金
12 Mar 2015	24 Feb 2015	08 Apr 2015	0.45 现金
11 Dec 2014	25 Nov 2014	08 Jan 2015	0.45 现金
11 Sep 2014	23 Jul 2014	07 Oct 2014	0.44 现金
12 Jun 2014	27 May 2014	08 Jul 2014	0.44 现金
13 Mar 2014	25 Feb 2014	07 Apr 2014	0.44 现金
12 Dec 2013	26 Nov 2013	08 Jan 2014	0.44 现金
12 Sep 2013	23 Jul 2013	07 Oct 2013	0.43 现金
13 Jun 2013	28 May 2013	08 Jul 2013	0.43 现金
13 Mar 2013	26 Feb 2013	05 Apr 2013	0.43 现金
13 Dec 2012	27 Nov 2012	08 Jan 2013	0.43 现金
13 Sep 2012	24 Jul 2012	05 Oct 2012	0.42 现金
13 Jun 2012	22 May 2012	09 Jul 2012	0.42 现金
13 Mar 2012	28 Feb 2012	06 Apr 2012	0.42 现金
13 Dec 2011	10 Nov 2011	09 Jan 2012	0.42 现金
13 Sep 2011	26 Jul 2011	07 Oct 2011	0.38 现金
13 Jun 2011	24 May 2011	08 Jul 2011	0.38 现金
11 Mar 2011	22 Feb 2011	07 Apr 2011	0.38 现金
13 Dec 2010	23 Nov 2010	07 Jan 2011	0.38 现金
13 Sep 2010	27 Jul 2010	07 Oct 2010	0.38 现金
11 Jun 2010	26 May 2010	08 Jul 2010	0.38 现金
11 Mar 2010	23 Feb 2010	07 Apr 2010	0.38 现金
11 Dec 2009	24 Nov 2009	08 Jan 2010	0.38 现金
02 Sep 2009	28 Jul 2009	01 Oct 2009	0.38 现金
04 Jun 2009	27 May 2009	01 Jul 2009	0.38 现金
04 Mar 2009	24 Feb 2009	01 Apr 2009	0.38 现金
03 Dec 2008	25 Nov 2008	02 Jan 2009	0.38 现金
03 Sep 2008	22 Jul 2008	01 Oct 2008	0.38 现金
04 Jun 2008	27 May 2008	01 Jul 2008	0.38 现金
05 Mar 2008	26 Feb 2008	01 Apr 2008	0.38 现金
05 Dec 2007	27 Nov 2007	02 Jan 2008	0.38 现金
05 Sep 2007	24 Jul 2007	01 Oct 2007	0.38 现金
06 Jun 2007	22 May 2007	02 Jul 2007	0.38 现金
07 Mar 2007	27 Feb 2007	02 Apr 2007	0.38 现金
06 Dec 2006	28 Nov 2006	02 Jan 2007	0.38 现金
30 Aug 2006	25 Jul 2006	02 Oct 2006	0.38 现金
31 May 2006	23 May 2006	03 Jul 2006	0.38 现金
31 Aug 2005	26 Jul 2005	03 Oct 2005	0.38 现金
01 Jun 2005	24 May 2005	01 Jul 2005	0.38 现金
02 Mar 2005	22 Feb 2005	01 Apr 2005	0.38 现金
01 Dec 2004	23 Nov 2004	03 Jan 2005	0.38 现金
01 Sep 2004	27 Jul 2004	01 Oct 2004	0.38 现金
02 Jun 2004	25 May 2004	01 Jul 2004	0.37 现金
03 Mar 2004	24 Feb 2004	01 Apr 2004	0.37 现金
03 Dec 2003	25 Nov 2003	02 Jan 2004	0.37 现金
03 Sep 2003	22 Jul 2003	01 Oct 2003	0.37 现金
04 Jun 2003	27 May 2003	01 Jul 2003	0.36 现金
05 Mar 2003	25 Feb 2003	01 Apr 2003	0.36 现金
04 Dec 2002	26 Nov 2002	02 Jan 2003	0.36 现金
04 Sep 2002	23 Jul 2002	01 Oct 2002	0.36 现金
05 Jun 2002	28 May 2002	01 Jul 2002	0.35 现金
06 Mar 2002	26 Feb 2002	01 Apr 2002	0.35 现金
05 Dec 2001	27 Nov 2001	02 Jan 2002	0.35 现金
30 Aug 2001	24 Jul 2001	01 Oct 2001	0.35 现金
31 May 2001	22 May 2001	02 Jul 2001	0.34 现金
07 Mar 2001	27 Feb 2001	02 Apr 2001	0.34 现金
06 Dec 2000	28 Nov 2000	02 Jan 2001	0.34 现金
30 Aug 2000	25 Jul 2000	02 Oct 2000	0.34 现金
31 May 2000	22 May 2000	03 Jul 2000	0.29 现金
01 Mar 2000	22 Feb 2000	03 Apr 2000	0.29 现金
01 Dec 1999	23 Nov 1999	03 Jan 2000	0.29 现金
01 Sep 1999	27 Jul 1999	01 Oct 1999	0.29 现金
02 Jun 1999	25 May 1999	01 Jul 1999	0.27 现金
03 Mar 1999	23 Feb 1999	01 Apr 1999	0.27 现金
02 Dec 1998	24 Nov 1998	04 Jan 1999	0.54 现金
02 Sep 1998	28 Jul 1998	01 Oct 1998	0.54 现金
03 Jun 1998	26 May 1998	01 Jul 1998	0.45 现金
04 Mar 1998	24 Feb 1998	01 Apr 1998	0.45 现金
03 Dec 1997	25 Nov 1997	02 Jan 1998	0.45 现金
03 Sep 1997	22 Jul 1997	01 Oct 1997	0.45 现金
05 Jun 1997	28 May 1997	01 Jul 1997	0.42 现金
05 Mar 1997	25 Feb 1997	01 Apr 1997	0.42 现金
05 Dec 1996	26 Nov 1996	02 Jan 1997	0.4 现金
04 Sep 1996	23 Jul 1996	01 Oct 1996	0.4 现金
06 Jun 1996	29 May 1996	01 Jul 1996	0.34 现金
06 Mar 1996	27 Feb 1996	01 Apr 1996	0.34 现金
06 Dec 1995	28 Nov 1995	02 Jan 1996	0.34 现金
05 Sep 1995	25 Jul 1995	02 Oct 1995	0.34 现金
02 Jun 1995	23 May 1995	03 Jul 1995	0.3 现金
显示更多

每年股息收益率

年份	每年总股息 ($)	频率/年份	收益率 %
2025	1.62	2	2.14
2024	3.08	4	3.10
2023	2.92	4	2.68
2022	2.76	4	2.49
2021	2.60	4	3.39
2020	2.44	4	3.13
2019	2.20	4	2.54
2018	1.92	4	2.63
2017	1.88	4	3.50
2016	1.84	4	3.28
2015	1.80	4	3.57
2014	1.76	4	3.25
2013	1.72	4	3.60
2012	1.68	4	4.30
2011	1.52	4	4.23
2010	1.52	4	4.42
2009	1.52	4	4.36
2008	1.52	4	5.24
2007	1.52	4	2.74
2006	0.760	2	1.83
2005	1.52	4	5.01
2004	1.49	4	4.86
2003	1.45	4	3.29
2002	1.41	4	2.61
2001	1.37	4	2.44
2000	1.21	4	1.35
1999	1.37	4	2.14
1998	1.89	4	2.69
1997	1.69	4	3.34
1996	1.42	4	3.74
1995	0.640	2	2.04
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

请登录以添加到您的群组

AI 建议策略模板

自定义的价格提醒

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

请登录以添加到您的群组

已实现利润	-
未实现利润	-
收到股息 2025	-
利润总额	-
平均回报	-
数量(购买)	-
平均价格(购买)	-
数量(卖出)	-
平均价格(卖出)	-

请登录以添加到您的群组

没有符合您标准的股票

营业毛利率	27.27%
营业利益率 (TTM)	39.26%
稀释每股收益 (EPS TTM)	6.88
季度收入增长率 (YOY)	-1.60%
季度盈利增长率 (YOY)	6.70%

总债务/股东权益 (D/E MRQ)	82.53%
流动比率 (MRQ)	1.37
营业现金流 (OCF TTM)	21.47 B
杠杆自由现金流 (LFCF TTM)	17.83 B

资产报酬率 (ROA TTM)	13.90%
股东权益报酬率 (ROE TTM)	40.79%

安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)